Eli Lilly’s weight loss revolution and what it means for the next decade

In just a few years Eli Lilly has moved from a steady mid‑pack pharma name to the company most closely associated with the new era of obesity drugs. Back in 2022 it generated around 28 billion dollars in revenue and its shares traded below 300 dollars, reflecting a solid but unspectacular portfolio. By 2025, sales had climbed above 65 billion dollars and tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, had become one of the most successful medicines in modern history. The multiple the market is willing to pay today is built almost entirely on the belief that this franchise can dominate obesity treatment for years to come.

For a long term investor, the question is not whether the story sounds exciting, but whether the current price already assumes too much. That means looking beyond headlines to growth rates, capacity build‑out, regulatory decisions and the rest of Lilly’s pipeline to see how much of future cash flow really comes from obesity and how much from other…